# Seizures When You Already Have Epilepsy

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/seizures-when-you-already-have-epilepsy

> A careful study of epilepsy and type 2 diabetes found fewer seizures with GLP-1s, and 60% lower mortality. No glucose-lowering drug does that, and the implausible number is the informative one.

## Key points

- Seizure recurrence HR 0.82, modest and plausible on its own.
- All-cause mortality HR 0.40 and hospitalization HR 0.35. Randomized trials find 15–20%.
- Matching on 82 covariates cannot fix unmeasured frailty, the best predictor of near-term death.
- An implausible mortality result casts doubt on the plausible results reported beside it.
- The abstract calls an HR of 0.82 (CI 0.69–0.96) not significant. That interval excludes 1.

If you already have epilepsy and are offered a GLP-1 for your diabetes, the question is whether it affects your seizures. A study of 8,688 matched pairs reports fewer seizures, with a hazard ratio of 0.82.[1] It also reports 60% lower mortality from the same comparison, and that second number is the reason to be careful with the first.

## What was done

Using electronic health records from a large multinational network, researchers identified adults with at least three epilepsy or recurrent-seizure diagnoses who also had type 2 diabetes. Those starting a GLP-1 were matched one-to-one against those starting a different glucose-lowering drug (an SGLT2 inhibitor, a DPP-4 inhibitor, a sulfonylurea or insulin), using propensity scores built from 82 covariates. That produced 8,688 matched pairs.

That is a serious piece of methodology. Eighty-two covariates is thorough, the sample is large, and the follow-up runs well over a year in both arms.

*Outcomes with GLP-1 initiation against other glucose-lowering therapy. RD is absolute risk difference.[1]*

| Outcome | Hazard ratio (95% CI) | Risk difference |
| --- | --- | --- |
| Seizure recurrence | 0.82 (0.78–0.86) | −2.1% |
| Status epilepticus | 0.75 (0.66–0.85) | −0.7% |
| Hospitalization | **0.35 (0.29–0.43)** | −2.6% |
| All-cause mortality | **0.40 (0.34–0.47)** | −4.8% |
| ICU admission | 0.82 (0.69–0.96) | −0.3% |

## Why the mortality figure is the tell

> **A 60% reduction in dying, and a 65% reduction in being hospitalized, from choosing one diabetes medication over another, is not a plausible drug effect.** [The cardiovascular outcome trials](https://glpwatchdog.org/research/lists/top-glp1-cardiovascular-studies) that establish these drugs’ mortality benefit were randomized experiments in higher-risk populations, and they report reductions in the range of 15% to 20%. An observational estimate two to three times larger than the randomized one is a signature, not a discovery.

The mechanism is well understood and has a name, and we set it out at length in [when a hazard ratio is too good](https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good), where the same shape appears in a study of psoriasis patients. In short: GLP-1 medicines go to people who are healthier, better insured and more engaged with their care, while the sickest and frailest disproportionately end up on insulin, which sits in the comparison group.

Propensity matching corrects for what is written in the record: diagnoses, medications, laboratory values, demographics. It cannot correct for what is not recorded. General frailty, the thing that best predicts who dies within two years, is largely not recorded. Eighty-two covariates matched on paper can still leave two groups of visibly different people.

> When the effect on death exceeds what randomized trials found, the extra is measuring who got the prescription.

## What that does to the finding you came for

The study is about seizures, and its seizure result is modest and biologically plausible: a hazard ratio of 0.82, an absolute risk difference of 2.1 percentage points. Taken alone, it would be a finding worth taking seriously.

It cannot be taken alone. It comes from the same comparison between the same two groups whose mortality difference demonstrates those groups were not alike. If unmeasured health explains most of a 60% mortality gap, it is also available to explain a 2.1-point seizure gap. Healthier people with better-controlled diabetes have fewer seizures for reasons that have nothing to do with which drug they were given.

The general point is that an implausible result does not sit quietly in its own row. It is evidence about the whole comparison, and it discredits the plausible findings beside it.

A separate question is whether these drugs affect the chance of *developing* epilepsy in the first place, rather than seizure recurrence in people who already have it. That is examined in [GLP-1s and epilepsy risk](https://glpwatchdog.org/research/glp1s-and-epilepsy-risk), and the pattern inside those numbers points the same way.

## One sentence we cannot reconcile

> The published abstract gives ICU admission as a hazard ratio of 0.82 with a 95% confidence interval of 0.69 to 0.96, and then states that this association was not statistically significant. An interval running to 0.96 does not include 1. We are reporting both statements rather than choosing the one that suits a reading; the full paper will explain it, and the abstract does not.

## To the authors' credit

They describe their own findings as hypothesis-generating and say they warrant confirmation in prospective studies before being translated into practice. That is the correct characterization, and it is not a formality: plenty of papers with weaker designs claim more.

What this analysis does establish is that the question is worth asking. There are mechanistic reasons to wonder whether these drugs affect seizure threshold, and a signal in 8,688 matched pairs is a reasonable basis for designing a trial. It is not a basis for prescribing.

## Frequently asked questions

### Do GLP-1 drugs reduce seizures in people with epilepsy?

An observational study found a 2.1 percentage point lower rate of seizure recurrence with GLP-1 initiation. The same study reported 60% lower mortality, which is far larger than randomized trials find, indicating the compared groups differed in health in ways the analysis could not adjust for.

### Why is a very large benefit a warning sign?

Because randomized trials put these drugs' mortality benefit at roughly 15% to 20%. An observational estimate of 60% is measuring who receives the prescription as much as what the prescription does. Healthier, better-insured, more engaged patients get GLP-1s, while the frailest often get insulin.

### Doesn't matching on 82 covariates fix that?

Only for what is recorded. General frailty, the strongest predictor of near-term death, is largely absent from structured health records. Two groups matched on paper can still be visibly different people.

### So should the seizure finding be dismissed?

Not dismissed, but not relied on. It comes from the same comparison whose mortality result shows the groups were unalike, and healthier patients have fewer seizures for reasons unrelated to their diabetes drug.

### What did the authors conclude?

That the findings are hypothesis-generating and warrant confirmation in prospective studies before being translated into clinical practice. That is the correct reading of this design.

## References

1. AbuAlrob MA, Hussein A, Abdellatif R, et al. Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy. Epilepsia. 2026. PMID: 41251033. https://pubmed.ncbi.nlm.nih.gov/41251033/

---

Cite as: GLP Watchdog, Nora Bissett, "Seizures When You Already Have Epilepsy", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/seizures-when-you-already-have-epilepsy

Canonical HTML page: https://glpwatchdog.org/research/seizures-when-you-already-have-epilepsy

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
